TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.070
-0.050 (-1.21%)
Nov 20, 2024, 4:00 PM EST - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TLSI stock have an average target of 12.1, with a low estimate of 10 and a high estimate of 16. The average target predicts an increase of 197.30% from the current stock price of 4.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TLSI stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +170.27% | Nov 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +170.27% | Nov 11, 2024 |
| Northland Capital Markets | Northland Capital Markets | Buy Initiates $13 | Buy | Initiates | $13 | +207.13% | Oct 25, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +145.70% | Sep 16, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +194.84% | Jun 27, 2024 |
Financial Forecast
Revenue This Year
29.94M
from 18.51M
Increased by 61.76%
Revenue Next Year
44.11M
from 29.94M
Increased by 47.30%
EPS This Year
-1.49
from -6.73
EPS Next Year
-1.21
from -1.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.2M | 50.7M | 71.0M | ||
| Avg | 29.9M | 44.1M | 61.2M | ||
| Low | 27.3M | 35.3M | 46.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.8% | 69.3% | 61.0% | ||
| Avg | 61.8% | 47.3% | 38.6% | ||
| Low | 47.4% | 17.9% | 4.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.43 | -1.04 | -0.55 |
| Avg | -1.49 | -1.21 | -0.98 |
| Low | -1.50 | -1.42 | -1.79 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.